NasdaqGM:CRSPBiotechs
CRISPR Therapeutics CEO Share Sale Tests Confidence In Gene Editing Story
CRISPR Therapeutics (NasdaqGM:CRSP) CEO Samarth Kulkarni has executed a significant insider sale of company shares.
The transaction involved a substantial portion of his holdings, drawing fresh attention to leadership confidence and alignment with shareholders.
This insider activity is being watched closely by investors looking to interpret potential signals beyond short term price moves.
For context, CRISPR Therapeutics recently closed at $53.35, with the stock up 26.9% over the past year...